Outcome
    Strong Evidence

    Omega-3 Fatty Acids for Inflammaging Reduction

    Omega-3 reliably lowers inflammatory cytokines and is the best-supported supplement for age-related inflammation.

    Overview

    Inflammaging - the chronic low-grade inflammation that accumulates with age - is one of the areas where omega-3s have unusually direct biomarker evidence, because the effect on IL-6 and TNF-alpha has been measured repeatedly.
    Randomised trials in older adults show reductions in IL-6, TNF-alpha and CRP with EPA and DHA supplementation, and secondary analyses of large trials such as VITAL have reported small reductions in biological ageing markers. The mechanism is not merely suppressive: omega-3s generate specialised pro-resolving mediators that actively terminate inflammation, a capacity that declines with age. What remains unproven is that lowering these markers extends healthspan. Inflammaging predicts frailty and disease, but reducing a predictor is not the same as changing the trajectory, and hard outcome data are limited.

    No studies are currently linked to this pairing

    This page reflects published clinical literature and conventional dosing rather than trial data attached to this outcome in our library.

    How It Works

    Inflammaging arises from accumulated senescent cells secreting inflammatory factors, mitochondrial dysfunction, gut barrier leakage and declining resolution capacity. The last of these is where omega-3s act most distinctively: resolution of inflammation is an active process requiring resolvins, protectins and maresins, which are synthesised from EPA and DHA.
    Alongside this, EPA competes with arachidonic acid for cyclooxygenase and lipoxygenase, shifting eicosanoid production toward less inflammatory species, and both fatty acids suppress NF-kB activation and NLRP3 inflammasome signalling, lowering IL-1beta and IL-6 output. Omega-3 supplementation therefore addresses the failure of resolution rather than blocking inflammation outright - a meaningful distinction from NSAIDs, which suppress the initiation phase and can impair resolution.

    Dosing & Protocol

    Anti-inflammatory dosing sits above general cardiovascular maintenance levels.
    ContextDoseFormTiming
    Inflammation reduction2-3 g combined EPA + DHA dailyConcentrated fish oilDivided, with meals
    Maintenance1-2 g combined EPA + DHA dailyFish oil or algal oilWith food
    Target statusOmega-3 index above 8 percentMeasured by red cell fatty acid testRecheck at 4 months
    Assessment window12-24 weeks-CRP and IL-6 change slowly; retest rather than guess

    Diet drives the ratio

    Cutting linoleic-acid-rich seed oils amplifies the effect, since omega-6 and omega-3 compete for the same enzymes. Supplementing while eating a highly omega-6 diet works against itself.

    Evidence

    There are currently no studies linked to this pairing in our library, so no study list is shown.
    Meta-analyses of randomised trials report significant reductions in circulating IL-6, TNF-alpha and CRP with omega-3 supplementation, with larger effects at higher doses, longer durations and in older or metabolically unwell populations. Secondary analyses from large trials have also reported modest reductions in epigenetic ageing measures. However, biomarker reductions are typically small in absolute terms, trial durations rarely exceed a year, hard outcomes such as frailty incidence, disability and mortality have not been reliably improved by omega-3 alone, and inflammaging is a composite concept without an agreed clinical endpoint.

    Markers down, longevity unproven

    Consistent reductions in inflammatory markers. No demonstration that this translates into a longer healthspan.

    Safety

    Omega-3s have an excellent long-term safety record. At 2 to 3 g daily, reflux, fishy repeat and loose stools are the common issues; taking divided doses with food and choosing low-oxidation products manages both tolerability and quality.

    Persistently raised CRP needs investigation

    Chronic inflammation can reflect infection, autoimmune disease or malignancy. An abnormal result should be interpreted by a clinician, not self-managed with supplements.

    At 3 g daily the antiplatelet effect becomes relevant for anyone on anticoagulants or facing surgery, and high-dose EPA formulations have been associated with a small increase in atrial fibrillation risk in cardiovascular outcome trials. Older adults on multiple medications should have this reviewed rather than assumed harmless.

    Interactions & Conflicts

    Interactions reflect bleeding risk and overlap with other anti-inflammatory approaches.
    Interacts withSeverityMechanismAction
    Warfarin and DOACs
    moderate
    		Additive antiplatelet effect at 3 g dailyDiscuss with your prescriber before high-dose use
    NSAIDs
    moderate
    		Additive bleeding risk; NSAIDs may also impair resolutionAvoid routine long-term NSAID use where possible
    Curcumin or high-dose polyphenols
    low
    		Complementary anti-inflammatory routesReasonable to combine
    High linoleic acid seed oils
    moderate
    		Compete for the same desaturase and oxygenase enzymesReduce intake to improve the omega-3 index
    Planned surgery
    moderate
    		Bleeding riskDiscuss stopping in advance

    References

    No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.